Nuvectis Pharma Earnings Call Transcripts
Fiscal Year 2026
-
A transformative in-licensing deal brings two late-stage drug candidates, NXP100 and NXP200, into the pipeline, expanding focus to complement-mediated diseases and oncology. NXP100 offers once-daily oral dosing with strong efficacy, while NXP200 shows promise in multiple tumor types.
-
The meeting confirmed a quorum and approved both the election of a director for a term through 2029 and the ratification of the independent auditor for 2026. Full voting results will be filed with the SEC and made available online.
-
NXP900, a highly selective SRC inhibitor, shows strong safety and potency in early trials, achieving up to 95% SRC inhibition and avoiding major side effects. Ongoing Phase I-B trials target enriched patient populations and include combinations with leading lung cancer therapies, addressing a large market with substantial unmet need.
Fiscal Year 2025
-
NXP900’s phase 1b program targets large unmet needs in advanced solid tumors, leveraging a unique Src inhibition mechanism and favorable safety profile. The oral combination with osimertinib is positioned to address resistance in non-small cell lung cancer, with multiple data readouts expected in 2026.
-
Phase 1B study for NXP900 has begun, targeting genetically defined advanced cancers as both monotherapy and in combination with EGFR/ALK inhibitors. The program leverages a strong cash position, robust preclinical and clinical data, and aims for significant market and regulatory milestones.
-
Two oncology drug candidates are advancing: NXP 800 is in phase 1B with dose optimization ongoing, and NXP 900, a highly selective SRC inhibitor, is nearing phase 1B with strong early data. Key clinical updates and potential expansion into larger markets are expected within two months.
Fiscal Year 2024
-
Two targeted oncology drugs are advancing in clinical trials, with NXP-800 showing early efficacy and safety improvements in ovarian cancer and NXP-900 demonstrating selectivity and promising preclinical synergy for resistant lung cancers. Financials remain strong, and the team has a proven track record.